Clinical Trial Update: To Evaluate the Pharmacokinetic of Diacerein and Rhein After Maximum Use in Patients With Epidermolysis Bullosa (EB) [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating diacerein and rhein after maximum use in patients with epidermolysis bullosa, completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Dystrophic Epidermolysis Bullosa
• Epidermolysis Bullosa
• Epidermolysis Bullosa Simplex
• Junctional Epidermolysis Bullosa

Drugs mentioned

• Diacerein (Diacerein)
• rhein (rhein)

Snippet

Sponsor: Castle Creek Pharmaceuticals, LLC | Conditions: Epidermolysis Bullosa (EB), Epidermolysis Bullosa Simplex | Phase 1 | Status: COMPLETED | Results posted: 2020-02-10